Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Treatment Period	STARTED	Tralokinumab	107
Treatment Period	STARTED	Placebo	108
Treatment Period	Safety Analysis Set	Tralokinumab	107
Treatment Period	Safety Analysis Set	Placebo	107
Treatment Period	Per Protocol Anaysis Set	Tralokinumab	88
Treatment Period	Per Protocol Anaysis Set	Placebo	78
Treatment Period	Full Analysis Set	Tralokinumab	106
Treatment Period	Full Analysis Set	Placebo	108
Treatment Period	COMPLETED	Tralokinumab	100
Treatment Period	COMPLETED	Placebo	89
Treatment Period	NOT COMPLETED	Tralokinumab	7
Treatment Period	NOT COMPLETED	Placebo	19
Safety Follow-up Period	STARTED	Tralokinumab	75
Safety Follow-up Period	STARTED	Placebo	75
Safety Follow-up Period	COMPLETED	Tralokinumab	16
Safety Follow-up Period	COMPLETED	Placebo	18
Safety Follow-up Period	NOT COMPLETED	Tralokinumab	59
Safety Follow-up Period	NOT COMPLETED	Placebo	57

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03562377/flow